Inovalis Real Estate Investment Trust (TSE:INO – Free Report) – Desjardins decreased their Q4 2024 earnings per share (EPS) estimates for shares of Inovalis Real Estate Investment Trust in a report released on Monday, November 11th. Desjardins analyst A. Leon now anticipates that the company will post earnings of ($0.01) per share for the quarter, down from their prior forecast of $0.01. Desjardins also issued estimates for Inovalis Real Estate Investment Trust’s FY2025 earnings at ($0.06) EPS and FY2026 earnings at ($0.14) EPS.
Inovalis Real Estate Investment Trust Stock Performance
Inovalis Real Estate Investment Trust (TSE:INO – Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported C($0.29) EPS for the quarter. The firm had revenue of C$3.52 million for the quarter.
Inovalis Real Estate Investment Trust Company Profile
Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Read More
- Five stocks we like better than Inovalis Real Estate Investment Trust
- Upcoming IPO Stock Lockup Period, Explained
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- Top Stocks Investing in 5G Technology
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- What is the Nasdaq? Complete Overview with History
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
Receive News & Ratings for Inovalis Real Estate Investment Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovalis Real Estate Investment Trust and related companies with MarketBeat.com's FREE daily email newsletter.